

<b>GENEA047</b> (see details)	230	Genea Biocell	Genea	09/30/2013
<b>GENEA042</b> (see details)	231	Genea Biocell	Genea	09/30/2013
<b>GENEA043</b> (see details)	232	Genea Biocell	Genea	09/30/2013
<b>GENEA057</b> (see details)	233	Genea Biocell	Genea	09/30/2013
<b>GENEA052</b> (see details)	234	Genea Biocell	Genea	09/30/2013
<b>NYUES12</b> (see details)	235	Christoph Hansis, MD, PhD	New York University School	12/23/2013
<b>NYUES11; abnormal karyotype</b> (see details)	236	Christoph Hansis, MD, PhD	New York University School of Medicine	12/23/2013
<b>NYUES13</b> (see details)	237	Christoph Hansis, MD, PhD	New York University School	12/23/2013
<b>NYUES8</b> (see details)	238	Christoph Hansis, MD, PhD	New York University School of Medicine	12/23/2013
<b>NYUES9</b> (see details)	239	Christoph Hansis, MD, PhD	New York University School of Medicine	12/23/2013
<b>NYUES10</b> (see details)	240	Christoph Hansis, MD, PhD	New York University School	12/23/2013
<b>KCL036; disease-specific mutation</b> (see details)	241	Dusko Ilic, King's College London	King's College London	12/23/2013
<b>KCL042; disease-specific mutation</b> (see details)	242	Dusko Ilic, King's College London	King's College London	12/23/2013
<b>KCL043; disease-specific mutation</b> (see details)	243	Dusko Ilic, King's College London	King's College London	12/23/2013
<b>GENEA096; disease-specific mutations</b> (see details)	244	Genea Biocell	Genea	01/29/2014
<b>GENEA090; disease-specific mutations</b> (see details)	245	Genea Biocell	Genea	01/29/2014
<b>GENEA091; disease-specific mutations</b> (see details)	246	Genea Biocell	Genea	01/29/2014
<b>GENEA089; disease-specific mutations</b> (see details)	247	Genea Biocell	Genea	01/29/2014
<b>GENEA097; disease-specific mutations</b> (see details)	248	Genea Biocell	Genea	01/29/2014
<b>GENEA098; disease-specific mutations</b> (see details)	249	Genea Biocell	Genea	01/29/2014
<b>GENEA085 ; disease-specific mutation</b> (see details)	250	Genea Biocell	Genea	01/29/2014

<b>GENEA082 ; disease-specific mutation, abnormal karyotype</b>	251	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA078 ; disease-specific mutation</b>	252	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA079 ; disease-specific mutation</b>	253	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA080 ; disease-specific mutation</b>	254	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA081 ; disease-specific mutation</b>	255	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA083; disease-specific mutations, abnormal karyotype</b>	256	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA084 ; disease-specific mutation</b>	257	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA086 ; disease-specific mutation</b>	258	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA087 ; disease-specific mutation</b>	259	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA088 ; disease-specific mutation</b>	260	Genea Biocell	Genea	01/29/2014
(see details)				
<b>GENEA077; disease-specific mutation</b>	261	Genea Biocell	Genea	01/29/2014
(see details)				

カナダ

Canadian Institutes of Health Research (CIHR)

<http://www.cihr-irsc.gc.ca/e/15255.html>

CIHR法により2000年に設立された、健康の研究に関する政府機関。  
資金提供、発展途上域への支援、成果・知識の移行を行う。

Cell line(s)	Publication citation	Source	Contact Information
CA1, CA2	PMID: 17572666	Dr. Andras Nagy, Mt. Sinai Hospital, Toronto	Nagy Lab, Samuel Lunenfeld Research Institute
CC1, CC3	PMID: 20555390	Dr. Derrick Rancourt, University of Calgary	Dept. of Biochemistry and Molecular Biology, University of Calgary

Nagy Lab, Samuel Lunenfeld Research Institute

Mouse ES cells

Line	Description	Source	MTA	Reference
R1	129, Very robust, excellent germline transmission	Nagy Lab	get MTA	PNAS
G4	F1 hybrid, superior developmental potential	Nagy Lab	get MTA	PNAS
C2	B6, excellent germline transmission, compatible with aggregation	Nagy Lab	get MTA	PLoS One
Z/Red	G4 derived Cre- excision-conditional dsRED expression	Nagy Lab	get MTA	genesis
dsRed*MST	G4 derived overall dsRED expression (derivative of Z/Red)	Nagy Lab	get MTA	genesis
R1(Oct4-GFP)	R1 derived, Oct4(promoter)- EGFP transgenic (Random integration)	Nagy Lab	get MTA	Biotechnol Bioeng

Human ES cells

Line	Description	Source	MTA	Reference
CA1	Adapted to enzymatic passaging, XY	Nagy Lab	get MTA	Nature Biotechnology
CA2	Adapted to enzymatic passaging, XY	Nagy Lab	get MTA	Nature Biotechnology

Note: the two lines are siblings

Mouse iPS cells

Line	Description	Source	MTA	Reference
miPS#1B	Dox inducible independent reprogramming factor	Nagy Lab	get MTA	Nature
miPS#6C	Dox inducible independent reprogramming factor	Nagy Lab	get MTA	Nature

Human iPS cells

Line	Description	Source	MTA	Reference
hiPS#60	Dox inducible unlinked reprogramming factors	Nagy Lab	get MTA	Nature
hiPS#61	Dox inducible unlinked reprogramming factors	Nagy Lab	get MTA	Nature
hiPS#66	Dox inducible unlinked reprogramming factors	Nagy Lab	get MTA	Nature
hiPS#60	Dox inducible unlinked reprogramming factors	Nagy Lab	get MTA	Nature

Horse iPS cells

Line	Description	Source	MTA	Reference
EiPSC	first horse iPSC line	Nagy Lab	get MTA	Stem Cell Rev.

英国

UK Stem Cell Bank

<http://www.ukstemcellbank.org.uk>

2002年の勧告に基づき。2003年1月に、MRCとBBSRCの基金によって設立。

2006年からは第二期に入り、研究会議からさらに助成。

提供する細胞株は、hES、初代MEFである。

ヒトESC株

Cell Line	Accession Number	Cell Type	Karyotype	Grade	Depositor	Country	Legal Agreements
BJNhem19	R-08-022	Human Embryoni	diploid	Research	JNCASR, Bangalore	India	MDDA/RUL
BJNhem20	R-08-021	Human Embryoni	diploid	Research	JNCASR, Bangalore	India	MDDA/RUL
CB660	R-08-035	Human Neural Stem Cell	diploid	Research	University of Edinburgh	UK	
Edi-2	R-07-023	Human Embryoni c	diploid	Research	University of Edinburgh	UK	MAA/MUL
Edi-4	R-07-025	Human Embryoni c	diploid	Research	University of Edinburgh	UK	MAA/MUL
KCL002-WT	R-06-028	Human Embryoni c	diploid	Research	King's College London	UK	MDDA/RUL
KCL003-CF	R-06-027	Human Embryoni c	Cystic Fibrosis mutation	Research	King's College London	UK	MDDA/RUL
KCL009-tra	R-08-011	Human Embryoni c	diploid	Research	Kings College London	UK	MDDA/RUL
Man-1	R-08-017	Human Embryoni c	diploid	Research	University of Manchest	UK	MDDA/RUL
Man-2	R-09-011	Human Embryoni c	diploid	Research	University of Manchest	UK	MDDA/RUL
Mel-1	R-08-001	Human Embryoni c	diploid	Research	Stem Cell Sciences Ltd.	Australia	MAA/MUL
NCL-1	R-05-015	Human Embryoni c	diploid	Research	University of Newcastle upon	UK	MAA/MUL

NCL-2	R-07-14	Human Embryonic	diploid	Research	University of Newcastle upon	UK	MAA/MUL
NCL-3	R-07-015	Human Embryonic	diploid	Research	University of Newcastle upon	UK	MAA/MUL
NCL-4	R-07-016	Human Embryonic	diploid	Research	University of Newcastle upon	UK	MAA/MUL
NCL-5	R-07-017	Human Embryonic	diploid	Research	University of Newcastle upon	UK	MAA/MUL
Nott-1	R-07-001	Human Embryonic	diploid	Research	University of Nottingham	UK	MDDA/RUL
Nott-2	R-07-002	Human Embryonic	diploid	Research	University of Nottingham	UK	MDDA/RUL
OXF2	R-11-002	Human Embryonic	diploid	Research	University of Oxford	UK	MDDA/RUL
Shef-1	R-05-007	Human Embryonic	diploid	Research	Pfizer	UK	MAA/MUL
Shef-2	R-05-028	Human Embryonic	diploid	Research	Pfizer	UK	MAA/MUL
Shef-3	R-05-008	Human Embryonic	diploid	Normal	University of Sheffield	UK	MDDA/RUL
Shef-6	R-05-031	Human Embryonic	diploid	Research	University of Sheffield	UK	MDDA/RUL
Shef-7	R-07-008	Human Embryonic	diploid	Research	Pfizer	UK	MAA/MUL
Shef-8	R-08-015	Human Embryonic	diploid	Research	Pfizer	UK	MAA/MUL

初代MEF細胞

Type of Requester	hESC line Only	hESC line and feeders	Feeders Only <sup>3</sup>
Academics	NA	£ 375	£330
Non Academics	£375	NA	£330

**UK Stem Cell Line Registry (外部リンク)**

下記メールアドレスを参照

<http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc003259.pdf>

米国

Wisconsin International Stem Cell (WISC) Bank

http://www.wicell.org/

ウィスコンシン州マディソンに本社を置く、WiCell社は1999年に設立された非営利団体。

細胞バンキング、細胞遺伝子テスト、細胞配布を行う。

臨床グレードの幹細胞提供、品質管理をしている。

提供する細胞株は、最初にJ.Thomsonによってもたらされた5株(WA01, WA07, WA09, WA13, WA14)から始めて、拡大。

提供する細胞株は、73株。

- hES細胞株: Natinal Stem Cell Bankからの株とWiCellが開発した株。
- 動物由来成分フリーで、臨床治療に適している。
- H9(WA09)株とH14(WA14)株: GMP条件下で管理されているので、臨床应用到に適している。対応する研究用細胞株: 前臨床使用のために提供。
- 改変hES細胞株: 遺伝子改変したもの。
- iPS細胞株: リプログラムしたもの。
- 疾患モデルiPS細胞株: leukemiaモデル細胞。
- 分化細胞株: 神経前駆細胞株。

•新規開発株

LT1e-OLIG2GFP株: 神経細胞のマーカーOLIG2を発現している時に蛍光タンパク質を発現するように操作。

分化した神経細胞を追跡することができ、容易に細胞集団を調製することができる。

BG01株: 運動ニューロンとオリゴデンドロサイト系譜の発達を研究するための新しい研究ツールとして、Viacyte's ES細胞株上に構築。

LT2e-H9CAGGFP株: H9(WA09)細胞株に構成的GFP発現をもたらす修飾を含む。ヒト疾患のモデル化を行う際に、系統の発達を研究するのに有用。

•トランスジーンフリーの4細胞株: IISH1i-BM1, IISH2i-BM9, IISH3i-CB6, IISH6i-CML17。

ウィスコンシン大学、Slukvin研究室からの株

2株は骨髓由来、1株は臍帯血由来、1株は慢性骨髓性白血病(CML)の骨髓由来

•神経幹細胞株: NSC-H14、NSC-H9。

Buck研究所のXiaminが作成。

H9(WA09)およびH14(WA14)を神経幹細胞(NSC)に分化。無フィーダー培養法を用いて作成した。

•iPS細胞株mND1-4とmND2-0

ウィスコンシン大学トムソン研究室からの細胞株

ヒトビトロネクテン上で、化学成分が判っているE8培地で作成。

Disease Model

Cell Line	Cell Type	Culture Platform	Karyotype	Blood Type	Genetic Mod. Keyw	Publication	Provider	Disease Model	Cell Line Alias	NIH Registry Approved
IISH6i-CML17	Human iPS	Feeder Independent - TeSR1 Medium	46,XX	N/A	N/A	Publication	University of Wisconsin (Slukvin)	Chronic Myeloid Leukemia	N/A	No
WA16	Human ES	Feeder Independent - TeSR1 Medium	47,XXY	B+	N/A	Publication	University of Wisconsin (Thomson)	Klinefelter Syndrome	N/A	Yes



**米国**

**Harvard Stem Cell Institute**

<http://www.hsci.harvard.edu/>

HSCIは2004年にハーバード大学によって設立された、大学・研究所・病院などの横断的な総合研究機関。

疾患プログラム:研究者と臨床医が共同し、基礎研究やその臨床応用を支援。

血液疾患プログラム;骨髄移植や臍帯血移植における血液幹細胞再生過程の分子レベルでの解明。

癌プログラム;癌細胞特異遺伝子やパスウェイの解明。

心血管疾患プログラム;心筋再生と心不全治療。

糖尿病プログラム;機能的B細胞の誘導、40以上のhES細胞株の樹立。

腎臓病プログラム;近位尿細管再生の研究。

神経病プログラム;神経変性疾患や外傷性疾患、特にALSの研究。

トランスレーション研究プログラム;細胞治療の臨床応用。

研究センター:治療スクリーニングセンターとiPSコア施設がある

治療スクリーニングセンター;幹細胞や幹細胞由来細胞に対する薬剤効果のスクリーニング。

iPSコア施設;新技術を用いて、20の疾患特異iPS細胞株を作成。

**Disease Model**

**◆Lines from Harvard University:**

<http://stemcelldistribution.harvard.edu/>

hESC lines と iPS linesを提供;MHSCBシート内のHUES参照

LINE	DISEASE	GENDER	TYPE	
39b	Amyotrophic lateral sclerosis (SOD1)	Female	iPS	
29e	Amyotrophic lateral sclerosis (SOD1/L144F)	Female	iPS	
29d	Amyotrophic lateral sclerosis (SOD1/L144F)	Female	iPS	
27e	Amyotrophic lateral sclerosis (SOD1/G85)	Female	iPS	
27b	Amyotrophic lateral sclerosis (SOD1/G85)	Female	iPS	

**◆Lines from Boston Children's Hospital:**

iPS line	Disease/control	Sex	Source of cells	Transduction system	Request form	Scientific paper
ADA-iPS3	ADA/SCID	Male	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Totth@childrens.harvard.edu">Judit.Totth@childrens.harvard.edu</a>	Paper
			Coriell: GM01390	3 factors: OSK		
BMD-iPS1	Becker Duchenne muscular dystrophy	Male	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Totth@childrens.harvard.edu">Judit.Totth@childrens.harvard.edu</a>	Paper
			Coriell: GM04569	4 factors: OSKM		
DS1-iPS4	Down Syndrome	Male	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Totth@childrens.harvard.edu">Judit.Totth@childrens.harvard.edu</a>	Paper
			Coriell: AG05397	4 factors: OSKM		

DS2-iPS10	Down Syndrome		ATCC		Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	
HD1-iPS1	Huntington disease	Female	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: GM04281	4 factors: OSKM	
HD1-iPS4	Huntington disease	Female	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: GM04281	4 factors: OSKM	
JDM-iPS1	Diabetes Mellitus Juvenile	Female	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: GM02416	3 factors: OSK	
JDM-iPS10	Diabetes Mellitus Juvenile	Female	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: GM02416	4 factors: OSKM	
PD-iPS1	Parkinson's disease	Male	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: AG20446	4 factors: OSKM	
PD-iPS5	Parkinson's disease		Coriell		Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	
PD-iPS11	Parkinson's disease	Male	Fibroblasts	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
				Coriell: AG20446	4 factors: OSKM	
SBDS-iPS2	Shwachman-Bodian-Diamond syndrome	Male	Mesenchymal stem cells	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
					4 factors: OSKM	
SBDS-iPS3	Shwachman-Bodian-Diamond syndrome	Male	Mesenchymal stem cells	Retrovirus	Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	Paper
					4 factors: OSKM	
GD iPS1	Gaucher disease		Coriell		Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	
DMD-iPS1	Duchenne muscular		Coriell		Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	
DMD-iPS2	Duchenne muscular		Coriell		Download and email to <a href="mailto:Judit.Toth@childrens.harvard.edu">Judit.Toth@childrens.harvard.edu</a>	